Compatibility of 17-α-Estradiol, Betamethasone, Finasteride, Melatonin, Prednicarbate, and Spironolactone in TrichoFoam: A Foaming Vehicle for Personalized Alopecia Treatments

    December 2024 in “ PubMed ”
    Bruna Marianni, Hudson Polonini
    Studysummary This study evaluates the compatibility of six active pharmaceutical ingredients, including finasteride and spironolactone, with TrichoFoam™, a foam vehicle used in personalized treatments for alopecia, though it does not report specific results.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on pubmed.ncbi.nlm.nih.gov →
    Discuss this study in the Community →

    Related research 4

    1. Similar Efficacy of Maintenance Treatment of Finasteride 1 mg Every Other Month Compared with Finasteride 1 mg Daily in Korean Men with Androgenetic Alopecia After Taking Finasteride 1 mg Daily for 1 Year Journal of The American Academy of Dermatology · 2020
    2. Use of Finasteride in the Treatment of Men With Androgenetic Alopecia Journal of Investigative Dermatology Symposium Proceedings · 2003
    3. Advances in the Treatment of Male Androgenetic Alopecia: A Brief Review of Finasteride Studies PubMed · 2001
    4. Finasteride Inhibits 5α-Reductase Activity in Human Dermal Fibroblasts: Prediction of Its Therapeutic Application in Androgen-Related Skin Diseases International Journal of Dermatology · 1995